Clinical Trial Update: BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer [NA]

View source ↗

Summary

This entry provides an update on the BettER trial, a biomarker-driven early therapeutic selection study in HR+ HER2- metastatic or unresectable breast cancer; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Unresectable Breast Cancer

Snippet

Sponsor: Washington University School of Medicine | Conditions: Metastatic Breast Cancer, Unresectable Breast Cancer | NA | Status: RECRUITING